RESUMO
HER2-positive breast cancer is highly aggressive and prone to recurrence and metastasis. T-DM1 (Ado-Trastuzumab Emtansine) is a new anti-HER2 targeted drug with targeting therapeutic effect and cytotoxic killing. It was officially approved by the National Medical Products Administration in February 2020, but there are few reports about its application in China. In this paper, a case of locally advanced HER2-positive breast cancer treated with T-DM1 was reported, and relevant literature was reviewed to improve the understanding of targeted drug T-DM1, in order to provide a new anti-HER2 treatment option for HER2-positive breast cancer patients.
RESUMO
Objective To study the effect of lincRNA-p21 on the proliferation of renal cell carcinoma.Methods The expression levels of lincRNA-p21in renal cell carcinoma tissues and their corresponding para-cancerous tissues from 17 patients in department of nephrology,Hua Xi hospital,was detected by RT-PCR.In addition,the expression of lincRNA-p21 was analyzed in human clear cell RCC cell line 786-O and human embryonic kidney cell line HEK-293.The cell proliferation,apoptosis and the expression of Bax、Noxa、Puma that participated in p53 signaling pathway were detected after lincRNA-p21 was downregulated with siRNA.Results The expression levels of lincRNA-p21was higher in renal cell carcinoma tissues and 786-O cells than para-cancerous tissues and HEK-293 cells respectively(P ＜ 0.05).The ability of proliferation was significantly increased after lincRNA-p21 siRNA treatment in 786-O cells,whereas the cell apoptosis was decreased (P ＜ 0.05).The mRNA expressions of Bax,Noxa,Puma were also dramatically decreased after lincRNA-p21 was downregulated(P ＜0.05).Conclusion LincRNA-p21 inhibits the cell proliferation of 786-O cells through participation in p53 signal transduction pathways.These data suggested that lincRNA-p21 maybe could be used as molecular targets for human RCC treatment.